Skip to main content
SpringerLink
Log in

Recombinant Full-Length Parathyroid Hormone (1–84)

A Viewpoint by David A. Hanley

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26 (5): 688–703

    Article  PubMed  CAS  Google Scholar 

  2. Hodsman A, Papaioannou A, Cranney A. Scientific Advisory Council of Osteoporosis Canada, Clinical Guidelines Committee, Writing Group on the Systematic Review of Parathyroid Hormone for the Treatment of Osteoporosis. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006 Jul 4; 175 (1): 48

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

    David A. Hanley

Authors
  1. David A. Hanley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanley, D.A. Recombinant Full-Length Parathyroid Hormone (1–84). Drugs 66, 2382 (2006). https://doi.org/10.2165/00003495-200666180-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666180-00010

Search

Navigation